Table 3.
Regression between E/A at 60–64 years and SBP and antihypertensive treatment at four time points with further adjustment for covariables
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Independent variable | β (95% CI)×10−3 | p Value | β (95% CI)×10−3 | p Value | β (95% CI)×10−3 | p Value | β (95% CI)×10−3 | p Value | β (95% CI)×10−3 | p Value | |
| Age 36 (n=1576) | SBP | 0.3 (−0.8 to 1.5) | 0.564 | 0.3 (−0.8 to 1.4) | 0.598 | 0.9 (−0.2 to 2.1) | 0.116 | 0.8 (−0.4 to 1.9) | 0.190 | 0.8 (−0.3 to 2.0) | 0.170 |
| Age 43 (n=1576) | SBP | 0.4 (−0.7 to 1.4) | 0.481 | 0.4 (−0.6 to 1.5) | 0.443 | 1.3 (0.2 to 2.3) | 0.024 | 1.1 (0.06 to 2.2) | 0.039 | 1.2 (0.1 to 2.2) | 0.036 |
| Age 53 (n=1576) | SBP | −1.4 (−2.2 to −0.7) | <0.001 | −1.5 (−2.3 to −0.7) | <0.001 | −1.0 (−1.8 to −0.1) | 0.025 | −0.7 (−1.5 to 0.1) | 0.099 | −0.7 (−1.5 to 0.2) | 0.118 |
| Age 60–64 (n=1576) | SBP | −1.8 (−2.6 to −1.1) | <0.001 | −1.8 (−2.6 to −1.0) | <0.001 | NR | NR | −1.5 (−2.2 to −0.7) | <0.001 | −1.4 (−2.2 to −0.7) | <0.001 |
| Age 36 | HTT | NR | NR | 70 (−80 to 220) | 0.356 | 59 (−89 to 207) | 0.430 | 70 (−73 to 214) | 0.338 | 70 (−74 to 241) | 0.339 |
| Age 43 | HTT | NR | NR | −35 (−131 to 62) | 0.443 | −36 (−133 to 61) | 0.464 | −27 (−131 to 77) | 0.613 | −17 (−127 to 93) | 0.761 |
| Age 53 | HTT | NR | NR | 27 (−16 to 70) | 0.221 | 25 (−18 to 69) | 0.248 | 40 (−3 to 83) | 0.067 | 42 (−2 to 85) | 0.059 |
| Age 60–64 | HTT | NR | NR | −25 (−58 to 9) | 0.149 | NR | NR | 1.4 (−33 to 35) | 0.936 | 2.9 (−32 to 37) | 0.871 |
Imputed (n=1576 for all models—with valid outcome and SBP at age 60–64 years). The variable β is regression coefficient for E/A versus SBP (mm Hg) or antihypertensive treatment (HTT). Model 1: adjusted for age sex and CRF attended. Model 2: model 1+HTT at given age (for SBP) or model 1+SBP at given age (for HTT). Model 3: model 2+SBP at 60–64 years. Model 4: model 3+T2DM+BMI+smoking status+physical activity status. Model 5: model 4+left ventricular mass indexed to body surface area. Numbers of individuals receiving HTT were 51 (2%), 107 (3%), 438 (15%) and 640 (27%) at age 36, 43, 53 and 60–64 years, respectively.
BMI, body mass index; CRF, clinical research facility; NR, not relevant; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.